Drug Development for the Therapy of Mitochondrial Diseases

Area of Science:

• Biochemistry
• Genetics
• Pharmacology

Background:

• Mitochondrial diseases are inherited or acquired disorders impacting cellular energy metabolism.
• Current therapeutic strategies are limited, with no FDA-approved drugs available.

Purpose of the Study:

• To assess how recent advances in understanding mitochondrial disease etiology and pathogenesis inform new drug development.
• To review registered clinical trials for novel experimental drug entities in mitochondrial disease therapy.

Main Methods:

• Comprehensive review of scientific literature on mitochondrial disease etiology and pathogenesis over the past two decades.
• Systematic analysis of all registered clinical trials involving new experimental drug entities for mitochondrial diseases.

Main Results:

• Growing knowledge of mitochondrial disease mechanisms is increasingly reflected in targeted drug design.
• Several experimental drugs are in various phases of clinical trials, showing promise for symptom alleviation and disease modification.

Conclusions:

• Despite challenges, significant progress has been made in developing novel therapeutic approaches for mitochondrial diseases.
• The landscape of mitochondrial disease drug development is evolving, with a potential for the first FDA-approved therapy in the near future.